HHC
BMRN icon

Hutchin Hill Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Hutchin Hill Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-19,400
Closed -$1.81M – 420
2017
Q3 		$1.81M Sell
19,400
-35,900
-65% -$3.17M 0.07% 227
2017
Q2 		$5.02M Buy
55,300
+1,200
+2% +$109K 0.17% 131
2017
Q1 		$4.75M Buy
54,100
+2,600
+5% +$231K 0.13% 172
2016
Q4 		$4.27M Buy
51,500
+2,800
+6% +$241K 0.15% 175
2016
Q3 		$4.51M Buy
48,700
+3,200
+7% +$301K 0.09% 122
2016
Q2 		$3.54M Buy
+45,500
New +$3.87M 0.12% 120

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hutchin Hill Capital's BMRN Position: Q4 2017 in Review

Hutchin Hill Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 19,400 shares — an estimated $1.81M sold.

Hutchin Hill Capital first reported a position in BMRN in Q2 2016 and held it in 6 quarters. The position peaked at $5.02M in Q2 2017. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

  • Hutchin Hill Capital reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Hutchin Hill Capital sold 19,400 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $1.81M.
  • Hutchin Hill Capital first reported a position in BioMarin Pharmaceuticals in Q2 2016 and held it in 6 quarters.
  • Hutchin Hill Capital's BioMarin Pharmaceuticals position peaked at $5.02M in Q2 2017.
  • 438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Hutchin Hill Capital's 13F filing for Q4 2017, filed 12 Feb 2018.